Method of preparing an undifferentiated cell

• US 7,220,412 B2
• Filed: 05/08/2002
• Issued: 05/22/2007
• Est. Priority Date: 02/02/1995
• Status: Expired due to Fees

• Current Assignee: Ghazi Jaswinder Dhoot
• Original Assignee: Ghazi Jaswinder Dhoot
• Inventors: Abuljadayel, Ilham Saleh
• Primary Examiner(s): Canella; Karen A.
• Application Number:
  US10/140,978
• Publication Number:
  US 20030138947A1
• Time in Patent Office: 1,840 Days
• Field of Search: 424/139.1, 424/152.1, 424/153.1, 424/154.1, 424/155.1, 424/172.1, 424/173.1, 424/174.1, 424/130.1, 424/141.1, 424/144.1
• US Class Current: 424/144.1
• CPC Class Codes: A61K 2035/124 the cells being hematopoietic, bone marrow derived or blood cells
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: C12N 2500/14 Calcium; Ca chelators; Calcitonin
• CPC Class Codes: C12N 2500/24 Iron; Fe chelators; Transferrin
• CPC Class Codes: C12N 2501/06 Anti-neoplasic drugs, anti-retroviral drugs, e.g. azacytidine, cyclophosphamide
• CPC Class Codes: C12N 2501/14 Erythropoietin [EPO]
• CPC Class Codes: C12N 2501/22 Colony stimulating factors (G-CSF, GM-CSF)
• CPC Class Codes: C12N 2501/39 Steroid hormones
• CPC Class Codes: C12N 2501/50 Cell markers; Cell surface determinants
• CPC Class Codes: C12N 2506/11 from blood or immune system cells
• CPC Class Codes: C12N 2506/45 from artificially induced pluripotent stem cells
• CPC Class Codes: C12N 2510/00 Genetically modified cells
• CPC Class Codes: C12N 5/0634 Cells from the blood or the immune system
• CPC Class Codes: C12N 5/0635 B lymphocytes
• CPC Class Codes: C12N 5/0636 T lymphocytes
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors

Abstract

Disclosed is a method of preparing an undifferentiated cell. The method includes contacting a more committed cell with an agent that causes the more committed cell to retrodifferentiate into an undifferentiated cell.

Claims

1. A method of increasing the relative number of CD34⁺ cells in a cell population comprised of hematopoietic cells, including committed cells, which method comprises:

(i) contacting the cell population with an antibody that operably engages an MHC class I antigen or an MHC class II antigen on said committed cells; and

(ii) incubating committed cells that are engaged by said antibody such that the relative number of CD34⁺ cells increases as a result of said engaging.

2. The method of claim 1 wherein the committed cells are hemopoietic cells.

3. A method according to claim 1 wherein said MHC class I antigen is a Human Leukocyte-Associated (HLA)-A receptor, an HLA-B receptor, an HLA-C receptor, an HLA-E receptor, an HLA-F receptor or an HLA-G receptor and said MHC class II antigen is an HLA-DM receptor, an HLA-DP receptor, an HLA-DQ receptor or an HLA-DR receptor.

4. The method according to claim 3 wherein the MHC class I antigen is an HLA-DR receptor.

5. The method according to claim 4 wherein the HLA-DR receptor comprises a β

-chain.

6. The method according to claim 5 wherein the β

-chain has homologous regions.

7. The method according to claim 6 wherein the HLA-DR receptor comprises at least the homologous region of the β

-chain of HLA-DR.

8. A method according to claim 1 wherein the antibody is a monoclonal antibody.

9. A method according to claim 8 wherein the antibody is selected from the group consisting of monoclonal antibody CR3/43 and monoclonal antibody TAL 1B5.

10. A method according to claim 9, wherein the antibody is CR3/43.

11. The method according to claim 1 wherein said incubating is from 2 to 24 hours.

12. The method according to claim 1 wherein the committed cells are non-cancer cells.

13. The method according to claim 1 wherein the committed cells are differentiated cells.

14. The method according to claim 1 wherein the committed cells include at least one cell type selected from the group consisting of T-cell colony-forming cells (CFC-T cells), B-cell colony-forming cells (CFC-B cells), cosinophil colony-forming cells (CFC-Eosin cells), basophil colony-forming cells (CFC-Bas cells), granulocyte/monocyte colony-forming cells (CFC-GM cells), megakaryocyte colony-forming cells (CFC-MEG cells), erythrocyte burst-forming cells (BFC-E cells), erythrocyte colony-forming cells (CFC-E cells), T-cells and B cells.

15. The method according to claim 1 wherein the CD34⁺ cells are Major Histocompatibility Complex (MHC) class I⁺ and MHC class II⁺ cells.

16. A method according to claim 1 wherein the antibody is used in conjunction with a biological response modifier.

17. A method according to claim 16 wherein the biological response modifier is an alkylating agent.

18. A method according to claim 17 wherein the alkylating agent is or comprises cyclophosphoamide.